Biologics / Biosimilars

(A-046) A Study of Granulocyte-Colony Stimulating Factor (G-CSF) Reference and Biosimilar Products using Real World Data to Emulate a Target Trial for Switching: A Biologics and Biosimilars Collective Intelligence Consortium Experience

(A-044) Biologic Therapy and All-cause Cancer Risk in Patients with Inflammatory Bowel Disease: A Nested Case-Control study

(A-042) Faricimab Usage in Neovascular Retinal Diseases: Real-World Data on Patient Demographics, Comorbidities, and Treatment Patterns

(A-045) Indication-Specific Market Share Dynamics of Biosimilars and Originators: A Focus on the TNF-α Inhibitor Market in South Korea

(A-043) Janus Kinase Inhibitors with the Risk of Hepatic and Renal Risks: a Nationwide Cohort Study with Active Comparator Design